20:26 , May 15, 2019 |  BC Extra  |  Financial News

May 15 Financial Quick Takes: Perceptive leads $60M round for ArcherDx; plus Applied Therapeutics’ IPO, IsoPlexis, Symphogen

ArcherDx completes $60M series B  New investor Perceptive Advisors led a $60 million series B round for ArcherDx Inc. (Boulder, Colo.) that the company plans to use to scale operations, advance its companion diagnostic program...
00:04 , Mar 9, 2019 |  BC Extra  |  Company News

Management tracks: Lundbeck hires first CBO; ICT opens U.S. office

Neurology company Lundbeck hired Keld Flintholm Jørgensen as its first CBO. Jørgensen, who will begin at H. Lundbeck A/S (CSE:LUN) April 4, is global head of strategic partnering at Roche (SWX:ROG;OTCQB:RHHBY). Innovative Cellular Therapeutics Co....
21:52 , Dec 1, 2017 |  BC Week In Review  |  Company News

ArcherDX to develop companion diagnostic for CC-122

ArcherDx Inc. (Boulder, Colo.) will develop and commercialize a companion diagnostic to identify diffuse B cell lymphoma patients who may best respond to CC-122 from Celgene Corp. (NASDAQ:CELG). CC-122 is a cancer pleiotropic pathway modifier...
07:00 , May 23, 2016 |  BC Week In Review  |  Company News

ArcherDx sales and marketing update

ArcherDx launched three FusionPlex Blood Cancer panels worldwide to run on the company’s Anchored Multiplex PCR system. The company said each panel evaluates 80-90 genes. ArcherDx Inc. , Boulder, Colo.   Business: Diagnostic  ...
07:00 , Sep 16, 2013 |  BC Week In Review  |  Company News

ArcherDx, Enzymatics deal

Tool supplier Enzymatics acquired cancer-centric sequencing kit and software company ArcherDx in a deal valued up to $50 million comprised of cash, equity and milestones. ArcherDx co-founder and CEO Jason Myers joined Enzymatics as CSO....
07:00 , Sep 16, 2013 |  BC Week In Review  |  Company News

Enzymatics management update

Enzymatics Inc. , Beverly, Mass.   Business: Supply/Service   Hired: Jason Myers as CSO, formerly CEO of ArcherDx Inc., which Enzymatics acquired  ...